



masterinvestor

RESEARCH • ANALYSE • INVEST

INVESTING IN THE AGE OF LONGEVITY



Sponsored by



#LONGEVITY

[TWITTER.COM/MASTERINVESTOR](https://twitter.com/masterinvestor)



[FACEBOOK.COM/MASTERINVESTOR](https://facebook.com/masterinvestor)

[LINKEDIN.COM/COMPANY/MASTERINVESTOR](https://linkedin.com/company/masterinvestor)



[YOUTUBE.COM/MASTERINVESTORCHANNEL](https://youtube.com/masterinvestorchannel)

WELCOME



Hello and welcome to Investing in the Age of Longevity.

As war, disease and inflation rage around the world, investors could be forgiven for feeling rather pessimistic. Today, though, should provide all of us with a much needed shot of optimism.

As our Chairman, Jim Mellon, recently noted, investors prepared to look beyond the immediate future will still find good investment opportunities out there, and the Longevity sector offers huge potential gains. Anyone who can offer increased healthspan and Longevity is going to make a lot of money.

Today we will hear from some of the most experienced and knowledgeable investors in the space, what they look for and how they go about it.

There are good reasons why investment in Longevity appears to be in rude health. There has been substantial growth in the number of companies operating in the Longevity space, and the ingenuity demonstrated by some of these companies is astonishing.

Today you will also hear from a selection of companies developing cutting-edge solutions across the full spectrum of Longevity research; Prevention, Diagnostics, Treatment and Renewal.

The combination of scientific endeavour and substantial investment has started to yield results. One of the companies you will hear from today, Juvenescence, now has products on the market, while LyGenesis, who presented at this event one year ago, is about to grow new organs inside a person. Such progress should leave us all inspired and confident that the future is bright and the Longevity sector is going to be a key part of that.

Both the science and business of Longevity seem to be approaching an inflexion point. The time for serious investors to get involved is now. I hope that you will find today an invaluable source of the information you need to take advantage of this world-changing opportunity.

Best regards,

Tim Corcoran
CEO, Master Investor

TIME	SESSION / TALK	SPEAKER
09:00-09:20	Registration	
	Introduction and Overview	
09:20-09:30	Welcome Remarks	Phil Newman <i>CEO, First Longevity</i>
09:30-09:50	Introduction	Phil Newman <i>CEO, First Longevity</i>
09:50-10:10	Clinical Pipeline	Aaron Weaver <i>Principle, Apeiron Investment Group</i>
	Pre-Clinical	
10:10-10:30	Research & Early Discovery	Sergey Jakimov <i>Managing Partner, LongeVC</i>
10:30-10:45	Pre-Clinical Investing	Petr Sramek <i>Co-founder, Chairman and Managing/General Partner, Longevitytech.fund</i>
10:45-11:15	Coffee	
11:15-11:30	Pre-Clinical Pitches 1	Alex Blyth <i>Chief Executive Officer & Founder, Lift BioSciences</i>
11:30-11:50	Pre-Clinical Pitches 2	Tom Benson <i>CEO, Mitrix Bio</i>
11:50-12:10	Investment	Fiona Miller <i>Managing Partner, quadraScope</i>
12:10-13:20	Lunch	
	Therapeutics & Translating Research	
13:20-13:40	Therapeutics	Patrick Burgermeister <i>KIZOO Technology Capital</i>
13:40-14:05	Translating Longevity Science	Kristen Fortney <i>Co-founder and CEO, BioAge</i>

PROGRAMME

TIME	SESSION / TALK	SPEAKER
14:05-14:20	Therapeutics & Clinical Pipeline	Stephen Helliwell <i>VP Discovery Biology, Board Director - Rejuvenon Senescence Therapeutics, Rejuvenon Life Sciences AG</i>
14:20-14:35	Matter Bioworks	Chris Bradley <i>Co-founder and CEO, Matter Bioworks</i>
14:35-14:55	Investing/Company Pitch	David Gill <i>CFO, Juvenescence</i>
14:55-15:15	Investing	Dani Saurymper <i>Portfolio Manager, Pacific Asset Management</i>
15:15-15:45	Coffee	
Non-Therapeutics		
15:45-16:00	Commercialisation of non-Therapeutics	Tom Weldon <i>Founder, Executive Chairman, Acting CEO, Ponce De Leon Health</i>
16:00-16:35	Panel Discussion: Investing in Longevity	Julia Varesko <i>Senior Analyst at Pacific Asset Management</i>
		Aaron Weaver <i>Executive Chair at Rejuvenon</i>
		Fiona Miller <i>Managing Partner at quadraScope</i>
16:35-16:50	Understanding and Measuring Aging	Peter Ward <i>Co-founder & CEO, Humanity</i>
16:50-16:55	Closing Remarks	Phil Newman <i>CEO, First Longevity</i>
16:55-17:00	Close	

SPEAKERS

Tom Benson

Tom Benson is CEO and Founder of Mitrix. He's a serial entrepreneur and scientist who has founded 4 successful software and science startups. He was also a manager at the Linac Coherent Light Source (LCLS) facility at Stanford Linear Accelerator National Science Laboratory, where he gained interest in the imaging of mitochondria via X-Ray Crystallography and Cryo EM.



Alex Blyth

Healthcare serial entrepreneur, biologist, and inventor. On a mission to develop curative therapies and companies that can create life-changing returns for everyone involved.

After losing his mother to Pancreatic Cancer, he made a deal with his then 3-year-old daughter that they would develop a cure for cancer to stop more little girls from losing their grandmothers. Since founding LIFT BioSciences, the company has gone on to develop the world's first neutrophil-based cancer cell therapy with excellent pre-clinical results in destroying all types of solid tumours.



Christopher Bradley

Chris Bradley is a serial entrepreneur who has co-founded and lead several successful startups including Loki Therapeutics and Mana Health which was acquired by Comcast NBC Universal, Inc. While at Comcast, Chris was an executive director responsible for leading the healthcare product strategy within the Strategic Development division. With over 15 years of C-suite experience in tech, health IT, and biotech, Chris is passionate about taking ambitious ideas and making them a concrete reality.



He is the primary inventor of over 15 patents and holds a BS in Neuroscience & Cell Biology from Rutgers University and MS in Computer Science from New York University's Tandon school of engineering.

Patrick Burgermeister

Patrick Burgermeister is an expert in life science investing with a double background in molecular biology (Biozentrum Basel) and business administration (HSG Sankt Gallen). He joined Kizoo in 2019 coming from the venture capital group BioMedPartners where he was one of the partners. Moreover, his industry career encompasses also banking (as a senior analyst for pharma/biotech) and pharma (as a senior portfolio manager at Novartis).



Patrick supports various biotech companies as a director on their boards, was a successful business developer for early-stage biotech companies and led collaboration and licensing deals with public and private companies. He headed business development at several companies including Apeiron Biologics and BioVersys.

Martin Ducker

Martin Ducker is the Chief Science Officer of Juvenescence Life, where he oversees the ideation and development of novel nutritional interventions to slow or reverse ageing. Martin joined Juvenescence as a post doc in 2018 and has held a number of roles spanning business development, operations and R&D. Prior to Juvenescence he worked for the Government Office For Science, MannBio Invest, Applied Strategies and St. James's Place plc.



Martin completed his DPhil in the Department of Physiology Anatomy and Genetic at the University of Oxford and MPhil in Bioscience Enterprise from the University of Cambridge. While at Oxford he was awarded both the EIS Gold Award and EPSRC Impact Acceleration Award for his DPhil research and won Imagine IF Oxford. He enjoys growing unusual vegetables in his allotment, cycling and scuba diving.

Kristen Fortney

Kristen Fortney is the co-founder and CEO of BioAge, a clinical-stage biotechnology company developing a pipeline of treatments to extend healthy lifespan by targeting the molecular causes of aging. The company uses its discovery platform, which combines quantitative analysis of proprietary longitudinal human samples with detailed health records tracking individuals over the lifespan, to map out the key molecular pathways that impact healthy human longevity. By targeting these pathways with a large and mechanistically diverse portfolio of drugs, BioAge is unlocking opportunities to treat and prevent diseases of aging in entirely new ways.



Kristen's scientific background is in aging biology and bioinformatics. She received her PhD in Medical Biophysics from the University of Toronto, followed by postdoctoral training at Stanford University, where she was a fellow of the Ellison Medical Foundation & American Federation for Aging Research.

David Gill

David Gill, the Chief Financial Officer of Juvenescence, is a Chartered Accountant (FCA) with extensive experience in both the US and UK in private and listed biotech companies.

Previously Group Controller of the company, David was attracted to Juvenescence because of its exciting programmes. He says, "targeting both prevention and treatment of age-related diseases, Juvenescence has a diverse pipeline that offers unique and exciting opportunities to investors."

Before joining Juvenescence, David was Head of Finance at NASDAQ-listed Silence Therapeutics in London, an RNAi biotech company. Prior to this he was at PwC for 10 years, most recently having worked on GlaxoSmithKline.

David enjoys keeping fit by mountain biking in his spare time.



Stephen Helliwell B.Sc. Ph.D.

Stephen Helliwell received his BSc Honours in Biochemistry from the University of Kent in 1992. During his PhD in Biochemistry (1996) at the Biozentrum, University of Basel, he identified one of the targets (Tor1p) of the anti-aging drug rapamycin. Following a short Post-Doctoral stay at the University of Bern, he moved to the Department of Biology at MIT as a Post-Doctoral Fellow, discovering ubiquitination factors controlling membrane protein sorting, and continued this research at the Biozentrum, University of Basel until 2005. He joined the Novartis Institutes of BioMedical Research in 2005, initially focusing on small molecule target identification using chemogenomic profiling. In 2011 he started a program to improve mitochondrial dysfunction – a hallmark of aging and managed pre-clinical NASH program teams from 2016 to 2020. He joined Rejuveron 2 years ago to manage the biology of multiple drug discovery programs in the healthy aging space, and to oversee the biology side of diligence for novel programs joining Rejuveron.



Sergey Jakimov

Sergey is a serial entrepreneur, having co-founded 3 deep-tech ventures (including Koatum and Vortex Oil Engineering) and raised more than \$20 million in venture funding. He has advised several other startups in the therapeutics space on fundraising, IP protection, and clinical trial strategies. He is also a Visiting Lecturer to several universities on venture capital and intellectual property rights and co-authored a master's program in Technology Law for the Riga Graduate School of Law.



Since 2018, he has led medical tech startup Longenesis, a cutting-edge company that unlocks the hidden value of biomedical data and accelerates novel drug treatment & discovery. Sergey holds a BSc in International Affairs from Rīga Stradiņš University and two MSc in Political Science and Government and Law and Finance from Central European University and Riga Graduate School of Law, respectively. He was named as a Forbes Latvia 30 Under 30 in technology and healthcare in 2020.

Fiona Miller

Fiona is a serial entrepreneur with 3 successful exits, including a 12x exit. She was founder and CEO of octoScope, sold to Spirent Communications in 2021; Founder and CTO of Azimuth Systems, sold to Anritsu in 2016; and VP of Engineering at Scope Communications, sold to Hewlett-Packard (now Keysight) in 1998. Fiona holds 10 patents and is the publisher of numerous articles, white papers and test reports on wireless technologies and standards.



Fiona has been an active angel investor in the rejuvenation industry and also serves on the board of Healthy Longevity Clinic. She avidly supports rejuvenation initiatives through philanthropy.

She has a BA in Computer Science and BS in Electrical Engineering from Columbia University, and Master's work from MIT.

Phil Newman

Phil Newman is Editor in Chief of www.Longevity.Technology, the key daily news platform for Longevity investment, research and new business.

As an international consultant for over 25 years Phil has delivered C-level management, marketing and business development expertise to start-ups, scale-ups and enterprises.



Market experience includes: Longevity; IoT; AI; Medical Devices; Biopharma; 3D Manufacturing; Smartgrid and Sustainability. He is the founder of First Longevity which operates 2 digital businesses in the field of Longevity, including Crowd Longevity: the digital platform for equity funding Longevity start-ups and scale-ups.

Petr Sramek

"There are no country borders in exponential technologies. Our only boundaries are where our curiosity and courage end, and we move these lines farther every day."

Petr has been a serial entrepreneur for more than 33 years who believes that science and technology can help humanity reach a new, better level of being. Petr's main focus is on the health and sectors. Petr is building science, funding, and business infrastructure to support faster adoption of health-span improving technologies. Petr is also engaged in finding solutions to major problems using brain-inspired AI and the latest advances in counterfactual learning, causal inference, and emergence at Whytics and working as Strategic Advisor at AGI research company GoodAI.



Petr is a founder of the Longevitytech.fund, former Entrepreneur in Residence at Singularity University, co-founder of the LongevityForum.EU, board member at Animal Biosciences (US), AgeCurve (UK), iamYiam (UK) and interim CEO of various companies under Longevity.builders.

Petr helps innovative teams in Artificial Intelligence and Longevity technology grow into confident companies with global ambitions. He provides advice on fundraising, strategy, and product management. He advises companies as a mentor at Foresight Institute and On Deck Longevity Biotech.

Thanks to his talent for explaining scientific and technology topics clearly and engagingly to any audience, Petr has become a sought-after speaker at professional conferences. The media often borrow Petr's articles. He provides commentaries on longevity and artificial intelligence topics for Czech TV, Czech Radio, professional healthcare and ICT journals, Forbes Next, and other media outlets. Petr is a founder of the AI Awards project in co-operation with Economia – a leading business media publishing house.

Petr has been featured in the group of 28 AI leaders in the flagship World Intellectual Property Organization study next to Nick Bostrom, Frank Chen, Martin Ford, Kai-Fu Lee, Andrew Ng, Ben Lorica, and others.

Peter Ward

Peter Ward is the co-founder & CEO of Humanity Inc – a consumer platform and at its simplest a health navigation app (using similar ML techniques as the WAZE traffic app) which guides users to slow their aging and thus stay healthy for longer. Their mission is to add 1 billion years of health back to humanity by 2030.



Peter is also co-founder and board director at ICE (International Conclave of Entrepreneurs) – a leading tech founder & investor network; a board director at Ocean Bottle, who's mission is to remove plastic waste from the oceans, and a governor of a school in north London.

Previously, Peter was co-founder & CEO at WAYN (Where Are You Now?) which became the world's largest travel social network, which sold to lastminute.com Group.

Aaron Weaver, CFA, LLM

Aaron Weaver is a Principal at Apeiron Investments, which is a private investment group (AUM: \$3.5bn) focused on cutting-edge science and technology that will drive the "next human agenda", an era of innovation driving human and societal well-being together plus planetary health. He is an executive director at Rejuveron Life Sciences, a clinical-stage biotechnology company developing therapies for age-related diseases. In addition, Aaron is also involved as part of the sponsor team at Frontier Acquisition Corp, a SPAC focused on longevity and healthcare. He was also involved as a founding team member at atai Life Sciences, a company that pioneered the development of psychedelic therapies through regulated drug development pathways. Moreover, Aaron is also a Board Director at Bionomics Limited and Alto Neuroscience, a pioneering AI-enabled CNS drug development company, and Forme Life, a consumer-focused connected fitness and wellness platform. Aaron has also been an assistant referee and regulatory consultant to the Ultimate Fighting Championship (UFC) more than a decade.



He is a Chartered Financial Analyst (CFA) and a registered solicitor in the United Kingdom. Prior to Apeiron, Aaron was an investment banker at Credit Suisse in London within the Capital Markets Solutions team and previously worked as a solicitor at Allen & Overy LLP, London from 2007 – 2013. He holds a Masters of Law from the Queensland University of Technology and a Bachelor of Business Administration from the University of Queensland.

Tom Weldon

Tom has 35 years of senior management experience, primarily in the medical device industry, both early stage and public companies. He is a well-known entrepreneur and venture capitalist and holds nearly two dozen patents. He has founded over a dozen companies, which in total have created over \$2 billion in shareholder value. He was also the co-founder and Chairman of a top quartile venture fund, Accuitive Medical Ventures, which raised a total of \$230 million across two funds, and is now fully invested. Tom is the Founder, Chairman and CEO of Ponce de Leon Health (PDLH), a company with a mission to extend the length and quality of human life. PDLH is the world leading longevity company, and the only company to have



demonstrated both safety and efficacy in humans with its product. The company has launched Rejuvant, a once-a-day pill shown to reduce biologic age, as measured by DNA methylation testing.

A recently published paper in *Aging*, demonstrated that subjects who took a DNAm test, then were on Rejuvant for an average of 7 months, then re-tested, had an average decrease in their biologic age of 8 years.

Tom co-founded The Innovation Factory in 1999 and served as its Chairman. Through his role at The Innovation Factory, he has co-founded AcuFocus, AqueSys, LipoSonix, Neuronetics, and Sebacia. He was a director on the RespiCardia board, prior to its sale to Zoll Medical, and was formerly the Chairman of LipoSonix, prior to its sale to Medicis.

He was previously the co-founder, Chairman, and CEO of Novoste Corporation, which utilized intracoronary radiation therapy for the treatment of restenosis. Tom was Chairman and CEO of Novoste from its inception in 1992 and led the company through its initial public offering in 1996. Prior to that, Tom was the co-founder and CEO of Novoste Puerto Rico until its sale in 1992. Before founding Novoste, Tom held positions with Arthur Young & Company and Key Pharmaceuticals in various business and project management roles.

Tom received his M.B.A in Operations and Systems Management from Indiana University in 1981 and his B.S. Industrial Engineer from Purdue University in 1977. Tom has been recognized by Purdue University in 2007 by receiving the Distinguished Engineer Alumni Award, Outstanding Industrial Engineer Award in 2006, and the Burton Morgan Entrepreneurship Award in 2005. He also received the Junior Achievement ImpACT Award in 2003.

Tom's major philanthropic focus is the Weldon School of Biomedical Engineering at Purdue University, established in 2004, and the Weldon Foundation, Inc. He also serves on the advisory board for the Purdue University Biomedical Engineering School, the Advisory Board for the Buck Institute for Research on Aging and the National University of Singapore School of Medicine International Council.

COMPANIES

quadraScope

quadraScope venture fund invests in rejuvenation medicine ventures that aim to reverse aging and enhance health by targeting the mechanisms of aging. Our strong track record of entrepreneurial success and fund management, and presence in Boston and Tel Aviv, top biotech innovation hubs, enables us to quickly take advantage of healthspan-enhancing innovations where and as they happen.

www.quadrascope.com



Longevity Technology

First Longevity is a media and finance business centered in the middle of the growing longevity market.



We facilitate the further growth and development of the longevity market by supporting early stage and growth businesses through our unparalleled network of investors, advisory panel/board and our media platform: www.longevity.technology

First Longevity offers capital raising and advisory services to health and longevity businesses globally. Through investor introductions and advisory services, we help take businesses through Pre-seed to Series B financing.

longevity.technology

Pacific Asset Management

Pacific Asset Management (PAM) is a fresh and progressive asset manager, rethinking the conventions of how asset management works for advisers, institutions, investors, asset owners and the industry. We continue to push the boundaries of technology, operational and investment research, to provide better solutions for our partners and clients.

www.pacificam.co.uk



Apeiron

Apeiron is an independent real asset investment and asset management firm with clients at the centre of everything that we do. We provide innovative, unconflicted strategic advice to a diverse client base of Sovereign Wealth Funds, Institutional Investors and Family Offices. Our value proposition depends on investment experience, open architecture and unbiased advice. We pride ourselves on always being on the same side of the table as our clients.

apeiron-investments.com

APEIRON®

BioAge

BioAge takes a human-centric, data-driven approach to identify the molecular features of healthy aging and reveal the causes of age-related diseases. By targeting aging with a large and mechanistically diverse portfolio of drugs, we will unlock opportunities to treat or even prevent these diseases in entirely new ways.

bioagelabs.com

BIOAGE

Humanity

Humanity's mission is to extend the healthspan of humanity. The consumer subscription service enables users to find out what actions they can take to slow their aging process and thus reduce the risk of disease by tracking key aging biomarkers (digital and blood).

www.humanity.health

HUMANITY

Juvenescence

Juvenescence is the most diversified biotech company focused exclusively on healthy aging. Our mission is to inspire and equip the world to reimagine a lifetime.

JUVENESCENCE™

Today, people are starting new careers in their 50's, having kids later, and enjoying life longer. However, bias persists everywhere. To many, aging means the inevitable decline in health and one's value to society.

The tides are turning. Science and technology are making breakthroughs in human healthspan. Juvenescence has brought together a coalition of the best scientists, physicians and investors. Our goal: to deliver cutting-edge therapies and products that will disrupt how we age, think and behave.

There are three pillars to this change. The first: we are entering a moment where we can modify aging based on insights into how cells age, the role of genes and proteins in human health and aging. For the first time, scientists are stimulating the body to regenerate healthier tissues and organs.

The second pillar changes our current healthcare model. Today, the system treats disease after people get sick. The new ecosystem will develop therapies to prevent these same pathologies and disease states. It's a permanent shift from the sick-treat paradigm.

The final pillar democratizes these important advances. We'll harness clinically-validated but more economically available therapies, such as supplements, and leverage social media to connect directly with the people who need them.

People will be empowered to make lifestyle changes, to take advantage of transformative therapies to live longer and healthier.

www.juvenescence.ltd

KIZOO Technology Capital

KIZOO provides mentoring, seed and follow-on financing with a focus on rejuvenation biotech.



Having been entrepreneurs, VCs and mentors in both, high growth tech and biotech companies ourselves for many years with multiple exits and massive value created for the company founders, we now bring this experience to the emerging field of rejuvenation biotech – a young industry that will eventually become much bigger than today's largest technology markets.

kizoo.com

LIFT BioSciences

LIFT BioSciences is a pre-clinical stage biotech developing the World's only Neutrophil based Cell Therapy Platform. The LIFT platform is allogeneic and can be used to produce different Immuno-Modulatory Alpha Neutrophils (IMANs) for treating a range of different therapeutic indications, including solid tumours. IMANs have the potential to overcome hurdles encountered by other cell therapies in the treatment of solid tumours.



LIFT's primary focus is to bring to market a first-in-class allogeneic innate cell therapy called Neutrophil based Leukocyte Infusion Therapy (N-LIFT) to deliver remission across multiple solid tumour indications, irrespective of origin, mutational burden or antigen expression. N-LIFT has an antigen independent mechanism of action and N-LIFT cells have an ability, superior to T-cells, to infiltrate tumours, function in a tumour microenvironment and recruit the rest of the immune system.

Early work has shown 100% curative outcomes in mice and promising human data in an FDA approved safety trial showing up to 80% tumour necrosis in a mix of late-stage carcinoma patients even at low dose. N-LIFT itself has shown >90% cytotoxicity in a range of challenging solid tumour types in patient derived tumour models, as detailed in a recent press release. The Company will have further tumour data in

pancreatic cancer, head and neck and mouse efficacy models to come through over the next few months and is moving to its first in man trial over the next 18 months.
www.liftbiosciences.com

LongeVC

LongeVC is an international venture capital firm investing in visionary biotech companies and founders. Focusing on seed and early-stage investment, our mission is to bring to market breakthrough biotech that will change lives and transform the nature of our health.
longevc.com



Longevitytech.fund

We are longevity investors with an established track record. Through Fund I, we have invested in 40+ companies that represent the most exciting opportunities in the field of longevity. Some of the companies in our portfolio have outperformed our expectations, and we are proud to say that they have surprised us both through their technological advances and sky high valuations.
www.longevitytech.fund



Matter Bioworks

Matter Bioworks is a longevity holding company focused on preserving genome integrity.



Our core assets comprise accurate mutation sequencing, improving endogenous DNA repair, removing somatic mutations, and removing overly corrupted cells altogether.

Our current co-founders include George Church, PhD., Jan Vijg, PhD., Alex Maslov, MD, PhD., Claudia Gravekamp PhD. and other top scientists.

www.matterbio.com

Mitrix Bio

Mitrix scientists have made an important discovery: Mitlets, tiny extracellular vesicles that flow by the hundreds of billions in the bloodstream delivering fresh mitochondria to cells to make them more youthful. We believe mitlets are "nature's own youth serum", the primary factor in health, disease, and lifespan.



By growing Mitlets in a bioreactor and injecting them into the body, Mitrix has already reversed the age of animals the equivalent of 30 human years. In 2023 Mitrix aims to test this in primates and humans.

Mitrix is advised by some of the leading scientist of the world including Dr. Tom Rando from UCLA and Dr. Michael Snyder from Stanford.

mitrix.bio

Ponce De Leon Health

Ponce De Leon Health is dedicated to developing, marketing and selling drug-free solutions that are clinically shown to be safe, and to reduce human biologic age. Rejuvant is our commercially available patented product and is a dietary supplement containing a timed release CaAKG with different vitamins for a unique Male version and Female version. Rejuvant remodels your DNA methylation patterns back to those present when you were younger. Rejuvant acts upon several mechanisms to improve healthspan (the healthiest years of living). The company is currently raising a \$10M+ C round of financing.



pdlhealth.com

Rejuveron

Rejuveron is a clinical-stage biotechnology company creating therapies to improve healthy aging. Its experienced drug discovery and development team applies a deep understanding of the biology of aging, alongside technological advances in biopharmaceutical R&D, to progress a new generation of medicines that will help people to age better and live longer.

rejuveron

Through its portfolio companies, each uniquely focused on preventing, repairing, or reversing the hallmarks of aging, Rejuveron is advancing a therapeutic pipeline that ranges from drug discovery to the clinic. Rejuveron's business model is to create or acquire innovative companies, each being held within a wholly-owned or majority-owned company.

Co-founded in 2019 by visionary investor, Christian Angermayer, Rejuveron has state-of-the-art incubator laboratory facilities and offices at its headquarters in Zürich's Bio-Technopark (Switzerland), as well as portfolio companies teams located in Spain and Belgium.

www.rejuveron.com

ORGANISED BY

masterinvestor

RESEARCH • ANALYSE • INVEST

Master Investor | www.masterinvestor.co.uk

Master Investor Limited is an investment media and events company that delivers independent, financial commentary and analysis to UK private investors and traders. Our goal is to inform and connect private investors with opportunities they can invest in.

Our activities include:

Events: Master Investor operates the annual Master Investor Show, an event that connects 5,000+ private investors to companies they can invest into. Master Investor also runs bespoke smaller scale events such as Investing in the Age of Longevity and Opportunities in Alternative Proteins, which serve to explore investment opportunities in specific industries.

Blog Content: Master Investor is the UK's leading free-to-read investment publication. We seek out investment themes that look set to shape the world in the coming years: the 'money trees', as our Chairman, billionaire investor Jim Mellon, calls them, then translate these into unique, high-quality investment features for our readers.

Audio/Video: The Master Investor podcast and YouTube channel showcase some of the keenest investor perspectives and company management interviews to inform and entertain private investors looking to make their money work harder.

MASTER INVESTOR SHOW 2023



GET YOUR
FREE
TICKET



CONNECTING INVESTORS WITH OPPORTUNITIES



BUSINESS DESIGN CENTRE

ISLINGTON, 18 MARCH 2023

MASTER INVESTOR SHOW 2023

INSPIRATION FOR YOUR INVESTMENTS

- Join up to 5,000 fellow investors at our flagship investment event.
- Talk directly to CEOs of companies you can invest in.
- Hear the UK's leading entrepreneurs and fund managers speak about future trends.

[MASTERINVESTOR.CO.UK/
TICKETS](https://www.masterinvestor.co.uk/tickets)

FIND OUT MORE ABOUT THE SHOW AT [MASTERINVESTOR.CO.UK/SHOW](https://www.masterinvestor.co.uk/show)